Business Context and Reporting Period
This Form 8-K was filed by Avra Medical Robotics, Inc. (the "Company") on April 7, 2023. The Company is an emerging growth company incorporated in Florida. The filing reports on a material definitive agreement entered into on April 7, 2023, with Dr. Frederic Moll. The Company is currently in the process of acquiring CardioVentures, Inc. ("CardioVentures") via a merger. Upon consummation of this merger, the Company will change its name to SS Innovations International, Inc. ("SSII").
Key Financial Metrics
The filing details a financing transaction rather than standard operating financial results. Key financial figures include:
- Initial Investment: $2,000,000 previously provided by Dr. Moll.
- Additional Investment: $1,000,000 provided on April 10, 2023.
- Total Interim Financing: $3,000,000.
- Use of Proceeds: Funding working capital needs of CardioVentures pending the merger.
- Debt Instrument: The financing was evidenced by 7% Automatically Convertible One-Year Promissory Notes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity beyond the specific financing transaction described.
Material Changes and Transaction Structure
The primary material change is the entry into an Investment Agreement to secure interim financing for the pending merger. The conversion of the $3,000,000 Interim Financing into equity is structured as follows:
- Initial Conversion: Prior to the merger, CardioVentures will issue shares to Dr. Moll representing 5% of the Company's fully-diluted common stock post-merger.
- Forfeiture Requirement: Dr. Sudhir Srivastava (owner of CardioVentures) must forfeit 2% of CardioVentures' shares to facilitate the issuance to Dr. Moll.
- Post-Merger Adjustment: Immediately after the merger, the Company will issue additional shares to Dr. Moll so that his total holding equals 7% of the Company's fully-diluted common stock.
- Valuation Adjustment: If the Company raises capital at a pre-money valuation of less than $100 million before listing on the NYSE or Nasdaq, Dr. Moll will receive additional shares to adjust his ownership based on the lowest valuation achieved.
Outlook, Risks, and Contingencies
Put Right Contingency: If the merger is not consummated on or prior to April 14, 2023, Dr. Moll has the right to exercise a "Put Right." This allows him to require the Company, CardioVentures, and Dr. Srivastava to purchase his interest in the Investment Agreement for cash.
- Repayment Terms: The repurchase price equals the Interim Financing principal plus a 7% annual return (computed on a 360-day year).
- Penalty Interest: If payment is not made within five business days of the notice, the return rate increases to 12% per annum until paid.
Risks: The transaction is contingent on the successful consummation of the merger with CardioVentures. Failure to close the merger by the specified deadline triggers a significant cash outflow obligation for the Company and its related parties.
Investor Verification Checklist
- Verify the status of the merger between Avra Medical Robotics, Inc. and CardioVentures, Inc. as of the April 14, 2023 deadline.
- Confirm whether the Company has raised capital at a pre-money valuation below $100 million, which would trigger additional share issuance to Dr. Moll.
- Review the definitive Investment Agreement (Exhibit 10.1) for specific covenants and conditions not summarized in the 8-K.
- Monitor the Company's ability to fund the Put Right obligation (principal plus 7% or 12% interest) if the merger fails.
- Check for the official name change to SS Innovations International, Inc. and subsequent stock listing status.